Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06136195 · ClinicalTrials.gov registry record · Phase 1
Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers
A Phase 1 study of Alcohol Use Disorder (AUD) and Alcohol Consumption, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
- 2
- Study locations
NCT06136195 is a Phase 1 study of Alcohol Use Disorder (AUD) and Alcohol Consumption that is actively recruiting participants, run by Yale University. The registered enrollment target is 63 participants, below the 1,822-participant average among 30 other Alcohol Use Disorder (AUD) trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06136195, a Phase 1 study of Alcohol Use Disorder (AUD) and Alcohol Consumption, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research study is to find out about the effects of a drug called mavoglurant on alcohol consumption.
Conditions Studied
Interventions
- DRUG Mavoglurant
Study Locations (2)
Connecticut
- Connecticut Mental Health Center (SAC and SATU) - New Haven
- Yale New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06136195
The ClinicalTrials.gov registry entry for NCT06136195 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,822-participant average among 30 other Alcohol Use Disorder (AUD) trials with a reported enrollment target (97% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Alcohol Use Disorder (AUD) appearing as the primary indexed condition, and to 1 intervention - of which Mavoglurant is the first listed.
NCT06136195 reports 2 study locations spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT06136195 about?
NCT06136195 is a clinical study titled "Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers". The purpose of this research study is to find out about the effects of a drug called mavoglurant on alcohol consumption.
What is the current status of trial NCT06136195?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2024-07-01. Estimated completion is 2026-05-31.
What conditions does trial NCT06136195 study?
This clinical trial studies the following conditions: Alcohol Use Disorder (AUD), Alcohol Consumption, Heavy Drinker.
What interventions are being tested in trial NCT06136195?
The interventions under investigation include: Mavoglurant (DRUG).
Who is sponsoring clinical trial NCT06136195?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06136195 being conducted?
This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder (AUD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms
RECRUITING · Phase 1
-
The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)
RECRUITING · Phase 1
-
Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study
RECRUITING · Phase 1
-
Diclofenac Dose Response Study
RECRUITING · Phase 1
-
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
RECRUITING · Phase 2
-
Recovery Through Inhibitory Learning, Self-Efficacy Building, Problem Solving, and Community Building
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.